Targeting tyrosine phosphorylation of pcna inhibits prostate cancer growth

Molecular Cancer Therapeutics

Volumn 10, Issue 1, 2011, Pages 29-36

  Zhao, Huajun ^a   Lo, Yuan Hung ^a   Ma, Li ^a   Waltz, Susan E ^a,b   Gray, Jerilyn K ^a   Hung, Mien Chie ^c,d,e   Wang, Shao Chun ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c China Medical University Hospital   (China)

^d China Medical University and Hospital   (China)

^e ASIA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; DNA; SYNTHETIC PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG TARGETING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PEPTIDES; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATIC NEOPLASMS; TYROSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78751558423     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0778     Document Type: Article

References (31)

1. Pendleton J, Pisters LL, Nakamura K, Anai S, Rosser CJ. Neoadjuvant therapy before radical prostatectomy: Where have we been? Where are we going? Urol Oncol 2007;25:11-8.
2. Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell 2007;129:665-79.
3. Ayyagari R, Impellizzeri KJ, Yoder BL, Gary SL, Burgers PM. A mutational analysis of the yeast proliferating cell nuclear antigen indicates distinct roles in DNA replication and DNA repair. Mol Cell Biol 1995;15:4420-9.
4. Lehmann AR. Translesion synthesis in mammalian cells. Exp Cell Res 2006;312:2673-6.
5. Essers J, Theil AF, Baldeyron C, van Cappellen WA, Houtsmuller AB, Kanaar R, et al. Nuclear dynamics of PCNA in DNA replication and repair. Mol Cell Biol 2005;25:9350-9. (Pubitemid 41507836)
6. Ulrich HD. How to activate a damage-tolerant polymerase: consequences of PCNA modifications by ubiquitin and SUMO. Cell Cycle 2004;3:15-8.
7. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 2003;116:3051-60.
8. Matunis MJ. On the road to repair: PCNA encounters SUMO and ubiquitin modifications. Mol Cell 2002;10:441-2.
9. Marti TM, Kunz C, Fleck O. DNA mismatch repair and mutation avoidance pathways. J Cell Physiol 2002;191:28-41.
10. Paunesku T, Mittal S, Protic M, Oryhon J, Korolev SV, Joachimiak A, et al. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol 2001;77:1007-21.
11. Kelman Z. PCNA: structure, functions and interactions. Oncogene 1997;14:629-40.
12. Komatsu K, Wharton W, Hang H, Wu C, Singh S, Lieberman HB, et al. PCNA interacts with hHus1/hRad9 in response to DNA damage and replication inhibition. Oncogene 2000;19:5291-7.
13. Lee JS, Kim HS, Jung JJ, Kim YB, Park CS, Lee MC. Correlation between angiogenesis, apoptosis and cell proliferation in invasive ductal carcinoma of the breast and their relation to tumor behavior. Anal Quant Cytol Histol 2001;23:161-8.
14. Bukholm IRK, Bukholm G, Holm R, Nesland JM. Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas. J Clin Pathol 2003;56:368-73.
15. Grossi F, Loprevite M, Chiaramondia M, Ceppa P, Pera C, Ratto GB, et al. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur J Cancer 2003;39:1242-50.
16. Heimann R, Ferguson D, Recant WM, Hellman S. Breast cancer metastatic phenotype as predicted by histologic tumor markers. Cancer J Sci Am 1997;3:224-9. (Pubitemid 127696556)
17. Wang L-F, Chai C-Y, Kuo W-R, Tai C-F, Lee K-W, Ho K-Y. Correlation between proliferating cell nuclear antigen and p53 protein expression and 5-year survival rate in nasopharyngeal carcinoma. Am J Otolaryngol 2006;27:101-5.
18. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res; 54:2496-503.
19. Temmim L, Luqmani YA, Jarallah M, Juma I, Mathew M. Evaluation of prognostic factors in male breast cancer. Breast 2001;10:166-75.
20. Haerslev T, Jacobsen GK, Zedeler K. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat 1996; 37:101-13.
21. Tachibana KE, Gonzalez MA, Coleman N. Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol 2005;205:123-9.
22. Visakorpi T. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma. J Pathol 1992;168: 7-13.
23. Kordek R, Biernat W, Debiec-Rychter M, Alwasiak J, Liberski PP. Comparative evaluation of p53-protein expression and the PCNA and Ki-67 proliferating cell indices in human astrocytomas. Pathol, Res Prac 1996;192:205-9.
24. Padmanabhan V, Callas P, Philips G, Trainer TD, Beatty BG. DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J Clin Pathol 2004;57:1057-62.
25. Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in TRAMP mice. J Biol Chem 2005; 280:25134-45.
26. Bravo R, Macdonald-Bravo H. Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites. J Cell Biol 1987;105:1549-54.
27. Wang S-C, Nakajima Y, Yu Y-L, Xia W, Chen C-T, Yang C-C, et al. Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol 2006;8:1359-68.
28. Ammosova T, Jerebtsova M,BeullensM, Lesage B, Jackson A, Kashanchi F, et al. Nuclear targeting of protein phosphatase-1 by HIV-1 Tat protein. J Biol Chem 2005; 280:36364-71.
29. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010-7. (Pubitemid 27265584)
30. Bonny C, Oberson A, Negri Sp, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK. Diabetes 2001;50:77-82.
31. Zhang Y, Yuan F, Presnell SR, Tian K, Gao Y, Tomkinson AE, et al. Reconstitution of 50-directed human mismatch repair in a purified system. Cell 2005;122:693-705.